Discover how Cyto-Facto Inc. and Dr. Shin Kawamata and his team are overcoming the unique challenges of living therapies—such as maintaining sterility, standardization, and traceability — by integrating Quality by Design (QbD), automation, and continuous monitoring. Learn how modular Cell Processing Centers (CPCs), advanced automation, and the CytoFactory4.0™ digital platform ensure data integrity, regulatory compliance, and real-time control of critical parameters. With Vaisala’s viewLinc Continuous Monitoring System, Cyto-Facto guarantees reliable, scalable, and safe production of advanced therapies, moving personalized medicine closer to everyday clinical practice.
To access the full article and gain deeper insights into Cyto-Facto’s groundbreaking approach, please fill out the form below. Discover how continuous monitoring and digital innovation are setting new standards for the safe and efficient manufacturing of cell and gene therapies.